Moloney murine leukemia virus (M-MuLV) is a replication-competent retrovirus which induces T-lymphoblastic lymphoma 2 to 4 months after inoculation. Enhancer sequences in the U3 region of the M-MuLV long terminal repeat, primarily the 75-bp tandem repeats, strongly influence the disease specificity and latency of M-MuLV. We investigated the role of GC-rich sequences downstream of the tandem repeats in the disease specificity of M-MuLV. A recombinant M-MuLV lacking 23 bases of a GC-rich sequence (-174 to -151), Delta 27A M-MuLV, was tested for pathogenesis in neonatal NIH Swiss mice. Delta 27A M-MuLV induced disease with a longer latency than did M-MuLV (7 versus 3 months) in >85% of inoculated mice. More interestingly, this virus showed an expanded repertoire of hematopoietic diseases. Molecular analyses and histopathologic examinations indicated that while 39% of mice inoculated with Delta 27A M-MuLV developed T-cell lymphoblastic lymphoma typical of wild-type M-MuLV, the majority developed acute myeloid leukemia, erythroleukemia, or B-cell lymphoma. Viral DNA corresponding to Delta 27A M-MuLV was detectable in most of the tumors analyzed. These findings indicate that the GC-rich region significantly influences the disease specificity and latency of M-MuLV.
Nonacute retroviruses do not encode oncogenes, and they induce disease (usually leukemias) slowly. One important mechanism in leukemogenesis due to these viruses is transcriptional activation of cellular proto-oncogenes by enhancer or promoter sequences in the viral long terminal repeats (LTRs) (3, 4, 25, 26, 30, 32) . The tissue specificity of the LTR enhancers strongly influences the resulting disease for these viruses, presumably because of the requirement for strong enhancer action in the differentiated target cell to cause proto-oncogene activation (2, 8, 9, 19, 27, 35) .
Moloney (M) murine leukemia virus (MuLV) causes T-lymphoblastic lymphoma when inoculated into neonatal mice, with a latency of 3 to 5 months (34) . Upstream regulatory elements in the U3 region of the M-MuLV LTR include a TATA element at -30 bp, a CCAAT motif at -70 bp, and enhancer sequences (-180 to -340 bp) (12, 18, 22) . The M-MuLV enhancers consist of two copies of a tandemly repeated 75-bp element; in addition, a GC-rich element immediately downstream of the tandem repeats has been identified (18) . Consistent with the T-lymphoid tumors caused by M-MuLV, the M-MuLV LTR has been shown to have strong promoter activity in T-lymphoid tumor lines, although it also shows considerable transcriptional activity in other cell types (27) . Experiments with LTR chimeras between M-MuLV and Friend MuLV (which induces erythroleukemia) have implicated the tandem repeats as primary determinants of disease specificity in the M-MuLV LTR (8, 16, 21, 31) . Binding sites for a multitude of nuclear transcription factors have been identified in the M-MuLV * Corresponding author. tandem repeats, and mutations in specific binding motifs were found to increase the latency of T-lymphoid disease (28, 29) . In addition, mutations in one enhancer core element altered the M-MuLV disease specificity somewhat (29) .
We previously described a series of infectious M-MuLVs with internal deletions in the LTRs (13) . One of these mutants, Delta 27A M-MuLV, contained a small (23 bp) deletion that specifically removed the GC-rich sequences downstream of the tandem repeats, leaving the tandem repeats intact. In this study, the pathogenic behavior of Delta Mo27A M-MuLV was tested. This virus showed a striking expansion in the types of resulting leukemias, including T and B lymphoid, acute myeloid, and erythroid leukemias. These results implicate the GC-rich sequences in the T-lymphoid specificity of the wild-type M-MuLV LTR.
MATERIALS AND METHODS
Virus stocks. The Delta 27A deletion has been described previously (13) . Molecular cloning of recombinant proviral plasmids carrying alterations in both the 5' and 3' LTRs has also been previously described (23) . Infectious Delta 27A M-MuLV virus stocks were produced by transfection of NIH 3T3 cells with a complete Delta 27A M-MuLV recombinant provirus. Twenty-four-hour viral supernatants were harvested from confluently infected producer cells. Virus titration and determination of relative infectivities were done as described previously (13) .
Virus inoculation. One-to two-day-old NIH Swiss mouse neonates were inoculated intraperitoneally with 5 x 103 PFU (as determined by XC plaque titration [5, 24] and high-molecular-weight DNA was extracted from the remainders as described previously (14) .
Molecular and histopathological characterizations. Restriction enzyme digests, agarose gel electrophoresis in Trisacetate buffer, and Southern blot hybridization procedures were performed as previously described (14 (1, 14) .
Hybridization probes. The TCR1 probe, the JH probe, and the IgL, probe have already been described (14) . Agarose gel-purified DNA fragments were labeled with [oL-32P]dCTP (>3,000 Ci/mmol; Amersham) by using the random-primer method (10) . Oligonucleotides were labeled at the 5' OH by using [y-32P]ATP (>5,000 Ci/mmol; Amersham) and polynucleotide kinase (Boehringer Mannheim).
Assays for infectious virus. Levels of circulating virus in serum were determined by XC plaque titration as described previously (5) . The extents of infection in splenocytes and thymocytes were determined by infectious-center assays on NIH 3T3 cells as previously described (7, 8) . Briefly, animals inoculated with wild-type or Delta 27A M-MuLV were sacrificed at 4 or 6 weeks postinoculation. Single cell suspensions of thymocytes and splenocytes were serially diluted, and 102 to 106 cells were cocultivated with NIH 3T3 monolayers (5 x 104 cells per 5-cm-diameter dish) in Dulbecco modified Eagle medium containing 10% calf serum and 2 pug of Polybrene per ml for 24 h. The medium (containing nonadherent cells) was then aspirated, and the monolayers were washed twice with phosphate-buffered saline and allowed to grow to confluency. Upon reaching confluency, the cultures were assayed for infectious virus by using the UV/XC syncytial plaque assay (24) . Briefly, infected NIH 3T3 cell monolayers were irradiated with UV light and overlaid with rat XC cells. The number of XC plaques was used to calculate the concentration of splenocytes or thymocytes acting as infectious centers.
RESULTS
Pathogenicity of Delta 27A M-MuLV. The Delta 27A LTR deletion has been described previously and is illustrated in Fig. 1 (13) . It consists of a 23-bp deletion from -174 to -151 bp in the U3 region of the M-MuLV LTR. Transient expression assays using LTR-bacterial cat gene fusions indicated that the promoter activity of the Delta 27A LTR in NIH 3T3 cells was 20 to 30% of that of the wild type M-MuLV LTR (13) . In contrast, infectious M-MuLV driven by the Delta 27A LTR showed relatively normal specific infectivitywithin 70% of that of wild-type M-MuLV. Thus, the GC-rich region was not essential for efficient virus replication in NIH 3T3 cells.
The pathogenicity of Delta 27A M-MuLV was tested by intraperitoneal inoculation of neonatal NIH Swiss mice. Animals were monitored for the appearance of disease, and moribund animals were sacrificed. Figure 2 shows mortality plots for Delta 27A M-MuLV and wild-type M-MuLV (isolate 43D). All mice inoculated with wild type M-MuLV developed typical T-lymphoblastic lymphoma with a mean latency of 3 months. In contrast, for mice inoculated with Delta 27A M-MuLV, 87% developed tumors with a mean latency of 7 months. Therefore, while Delta 27A M-MuLV had a specific infectivity similar to that of wild-type M-MuLV in tissue culture, it had noticeably reduced pathogenicity in whole animals.
Diseases induced by Delta 27A M-MuLV. Tumors induced by Delta 27A M-MuLV were diagnosed by gross pathologic and histopathologic examinations, molecular analyses, and examination of peripheral blood smears. In contrast to wild-type M-MuLV, which induced T lymphoma exclusively, Delta 27A M-MuLV induced tumors from a variety of Deletion of sequences lying within the GC-rich regiop resulted in development of T-cell lymphoma, erythroleukemia, acute myeloid disease, and occasionally B-cell lymphoma. A comparison of the latencies of the different kinds of leukemia induced by Delta 27A M-MuLV is shown in Fig.  3 . Delta 27A M-MuLV induced T-cell lymphoma in a proportion of inoculated mice but with a considerably longer latency than that observed for wild-type M-MuLV. Animals diagnosed with T-cell-derived tumors became moribund 4.5 to 9.5 months postinoculation instead of the 2 to 4 months observed for wild-type M-MuLV-inoculated mice. On the average, T-lymphoid and erythroid malignancies appeared more rapidly (mean time, ca. 6 months) than did myeloil leukemias and B lymphomas (mean time, 8 to 9 months).
However, there was considerable overlap of the timp courses of the different tumors.
Detection of Delta 27A M-MuLV in tumors. Given the relatively long latency and wide spectrum of leukemias induced by Delta 27A M-MuLV, it was important to test whether the resulting tumors contained the input virus. For instance, it was possible that additional deletions or rearrangements within the LTR were necessary to induce some or all of the diseases. Therefore, tumor DNAs were analyzed for the presence of Delta 27A M-MuLV provirus by digestion with PvuII and Southern blot hybridization. Digestion of wild-type or Delta 27A M-MuLV proviral DNA with PvuII yields a 1.7-kb fragment containing sequences from the upstream LTR (Fig. 4A) . Since the Delta 27A deletion comprises only 23 bp, analyses on the basis of restriction fragment size differences were impractical. Therefore, a synthetic oligonucleotide probe spanning the Delta 27A deletion (and unique to this virus) was used to screen the blots. As shown in the top part of Fig. 4B and Table 1 , virtually all of the mice examined were positive for Delta 27A M-MuLV. As expected, an M-MuLV-specific oligonucleotide probe corresponding to the sequences deleted from the Delta 27A LTR did not hybridize to any of the tumor DNAs, as shown in the bottom part of Fig. 4B . These results confirmed that the resulting tumors were infected with M-MuLV driven by the Delta 27A LTR.
Virus infection in preleukemic mice. The extent and distribution of virus infection for Delta 27A M-MuLV wer,e compared with those of wild-type M-MuLV to determine whether they reflected the pathogenic behaviors. The levels of circulating virus were measured by XC plaque assays op sera taken from mice at 4 and 6 weeks postinoculation (Fig.   5a ). At erythroid showed a JH rearrangement. The initial diagnosis of erythroleukemia was based on histopathologic findings and evidenced by the presence of erythroblasts and associated areas of erythroid differentiation (i.e., normoblasts) in greatly expanded red pulp. Genomic analyses indicated that these mice also had clonal lymphoid cell proliferations (two pre-B and three T). On histologic reexamination, however, these five animals had expanded white pulp areas which contained neoplastic lymphoblasts. These five animals were therefore diagnosed as having two separate and distinct neoplasms (i.e., erythroleukemia and lymphoblastic lymphoma).
wider spectrum of tumor types than wild-type M-MuLV, it was interesting to test whether this was reflected in the distribution of viral infection among different hematopoietic cells. It might be expected that the relative infection in non-T-lymphoid cells for Delta 27A M-MuLV would be higher than for the wild-type virus, since disease specificity and tissue tropism of infection are generally correlated (17) .
One convenient approach was to compare the relative infection levels of thymocytes (virtually purely T lymphoid) and splenocytes (B lymphoid, T lymphoid, and myeloid). Infectious-center assays for splenocytes and thymocytes at 4 and 6 weeks postinoculation are shown in Fig. 5b . Contrary to our expectations, Delta 27A M-MuLV actually showed a relatively lower efficiency of splenocyte versus thymocyte infection than did wild-type M-MuLV, even though the former virus induced both non-T-lymphoid and T-lymphoid tumors while the latter caused only T lymphomas. Thus, for Delta 27A M-MuLV, organ tropism of infection did not directly correlate with the resulting tumor type. Similar results from pathogenicity studies of chimeric M-MuLVs suggest that thymotropism alone does not determine T-cell lymphoma-inducing potential (35) .
DISCUSSION
In this report, the pathogenic behavior of an M-MuLV deletion mutant lacking the GC-rich sequences downstream of the enhancer tandem repeats was investigated. In comparison with wild-type M-MuLV, Delta 27A M-MuLV showed two significant changes: a moderate increase in disease latency, and a striking expansion of leukemia types. This was particularly noteworthy because in tissue culture, Delta 27A M-MuLV has a relatively normal infectivity-toparticle ratio. These experiments indicate that the GC-rich sequences contribute to the T-lymphoma specificity of the M-MuLV LTR. While the importance of the GC-rich sequences in promoter activity in NIH 3T3 cells has been reported by Laimins et al. (18) , previous experiments have generally emphasized the tandem repeats as being responsi- ble for the tissue specificity of the M-MuLV LTR (2, 9, 16, 21, 31 ).
An attractive explanation for these results could be the interaction of nuclear factors binding to different DNA elements in the M-MuLV LTR. In this regard, Golemis et al. studied LTR chimeras between Friend MuLV (erythroleukemogenic) and M-MuLV (11). They found that combining elements of the Friend MuLV and M-MuLV enhancer regions could reduce the pathogenic potential in some cases. In particular, a chimeric LTR containing enhancer sequences from M-MuLV and GC-rich sequences (or their analogs) from Friend MuLV yielded a virus that induced T lymphomas with reduced efficiency. They suggested that interaction between cellular factors that bind to the enhancers and those that bind to the GC-rich sequences is necessary for maximal tissue specificity and activity of the LTR. Our results obtained with Delta 27A M-MuLV are completely consistent with this interpretation. In the case of the Delta 27A LTR, the GC-rich sequences were deleted. As a result, the cognate cellular factor would not bind and could not interact with proteins that bind to the enhancers, which may have effectively reduced the T-lymphoid specificity of One somewhat surprising aspect of this work was the fact that Delta 27A M-MuLV did not show a reduction in in vivo thymocyte infection relative to splenocyte infection in parallel with the expanded spectrum of leukemias induced. In fact, the opposite was observed (Fig. Sb) Delta 27A M-MuLV will be a valuable tool for studying aspects of M-MuLV pathogenesis, particularly tissue specificity of disease. In addition to the well-documented process of proto-oncogene activation, which probably occurs late in leukemogenesis, we and others have described early virusinduced preleukemic changes (7) . It is possible that the expanded disease spectrum involves early or late events or both. Delta 27A M-MuLV also is unusual in that it induces rhultiple types of leukemia under one experimental protocol. Most other nonacute retroviruses induce one type of disease in a given protocol, although a mutant of M-MuLV containihg specific mutations in an enhancer core element has been 4 WEEKS a 10 7 6 10 - 
